Hampered CD8 + ILT2 + T cell activation by HLA-G suggests a new immune checkpoint in gastric adenocarcinoma

Prior research has shown that immune checkpoint inhibitors (ICI) represent a transformative advancement in the clinical management of various malignancies by releasing the brakes on the immune system. Despite this progress, a substantial proportion of individuals diagnosed with advanced cancers fail to achieve durable responses to existing programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade. The tumor microenvironment often employs alternative, non-classical immunosuppressive mechanisms to evade detection and destruction by the host immune system. One such mechanism involves the interaction between non-classical human leukocyte antigen G (HLA-G) and its inhibitory receptors, such as immunoglobulin-like transcript 2 (ILT2), on effector cells. Understanding how these non-classical pathways function in specific cancers like gastric adenocarcinoma remains a priority for improving patient outcomes and overcoming resistance. The complexity of the immune landscape in gastric tumors necessitates the identification of novel biomarkers that predict treatment efficacy. This absence of evidence motivated the current investigation into the role of the HLA-G/ILT2 axis in modulating cytotoxic T cell activity within this specific patient population.

This research evaluates the functional implications of the HLA-G/ILT2 signaling axis within the cytotoxic T cell populations of patients diagnosed with gastric adenocarcinoma. The investigators sought to determine if the immunoglobulin-like transcript 2 (ILT2) receptor is differentially expressed on CD8+ T cells in the context of gastric malignancy compared to healthy individuals. A primary goal involved assessing how the presence of HLA-G affects the effector functions, specifically interferon-gamma (IFNγ) production and cellular proliferation, of these specific T cell subsets. The study also aimed to clarify the relationship between ILT2 expression and the well-characterized PD-1 checkpoint to identify potential overlaps or independent pathways. By characterizing these interactions, the team intended to validate the HLA-G/ILT2 pathway as a viable target for future immunotherapy. They focused on the specific vulnerability of ILT2-positive cells to tumor-derived inhibitory signals. This investigation provides a foundation for developing more precise interventions for gastric cancer patients.

The experimental design utilized peripheral blood mononuclear cells (PBMCs) and tissue infiltrating lymphocytes (TILs) harvested from 16 patients with gastric adenocarcinoma and 17 healthy control subjects. Researchers employed multi-color flow cytometry to quantify the frequency and phenotype of CD3+CD8+ILT2+ (ILT2+ Tc) cells across the different cohorts. Functional assays involved the stimulation of T cells via anti-T-cell receptor (TCR) antibodies to measure the secretion of interferon-gamma (IFNγ) as a marker of activation. Proliferation assays were conducted over a five-day period to observe the expansion of cytotoxic T cells in the presence or absence of exogenous HLA-G. The team also performed simultaneous staining for PD-1 and ILT2 to map the co-expression patterns of these inhibitory receptors on the cell surface. Statistical analyses, including p-value calculations for population comparisons and functional changes, ensured the robustness of the observed differences. These methods allowed for a comprehensive comparison between systemic immune profiles and those found directly within the tumor tissue.

Patients with gastric adenocarcinoma exhibited a significant overrepresentation of CD3+CD8+ILT2+ cells compared to healthy controls (p < 0.0001), despite having lower overall CD3+ counts (p = 0.0036). The ILT2+ Tc subset demonstrated a higher baseline capacity for IFNγ production upon TCR stimulation than the ILT2-negative counterparts (p = 0.0039). However, the introduction of HLA-G significantly impaired this IFNγ production in the ILT2+ population (p = 0.0002). Proliferative responses of these cytotoxic T cells were also markedly reduced by the presence of HLA-G after the five-day stimulation period (p < 0.0001). Analysis of co-expression revealed that ILT2 is expressed on CD8+ T cells independently of PD-1, with distinct patterns observed among individual patients. These findings suggest that ILT2+ T cells in these patients are uniquely susceptible to suppression by HLA-G-positive tumor cells. The data indicates that the HLA-G/ILT2 interaction acts as a potent suppressor of both cytokine release and clonal expansion.

The study identifies the HLA-G/ILT2 pathway as a distinct and potent immune checkpoint that contributes to the immunosuppressive landscape of gastric adenocarcinoma. These results indicate that targeting this axis could provide a therapeutic alternative for patients who do not respond to conventional PD-1 or PD-L1 inhibitors. The overrepresentation of ILT2-expressing CD8+ T cells suggests that these cells are a major component of the anti-tumor response that is being actively neutralized. Future clinical strategies might involve personalized immunotherapeutic approaches that specifically block the interaction between HLA-G and ILT2. Such interventions could restore the proliferative capacity and cytokine production of tumor-infiltrating lymphocytes. Ultimately, the researchers conclude that HLA-G plays a significant immunomodulatory role within the tumor microenvironment of gastric malignancies. This pathway represents a promising target for expanding the reach of modern oncology treatments.